OBI Pharma (4174) - Total Liabilities

Latest as of June 2026: NT$495.56 Million TWD ≈ $15.61 Million USD

Based on the latest financial reports, OBI Pharma (4174) has total liabilities worth NT$495.56 Million TWD (≈ $15.61 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 4174 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

OBI Pharma - Total Liabilities Trend (2011–2025)

This chart illustrates how OBI Pharma's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 4174 current and non-current assets.

OBI Pharma Competitors by Total Liabilities

The table below lists competitors of OBI Pharma ranked by their total liabilities.

Company	Country	Total Liabilities
Distribuidora de Gas Cuyana SA BA:DGCU2	Argentina	AR$152.18 Billion
Topower Co Ltd TWO:3226	Taiwan	NT$624.18 Million
Equillium Inc NASDAQ:EQ	USA	$3.57 Million
MFS High Income Municipal Closed Fund NYSE:CXE	USA	$83.53 Million
Genovate Biotechnology Co Ltd TWO:4130	Taiwan	NT$126.05 Million
Hansae Yes24 KO:016450	Korea	₩2.11 Trillion
Hwaseung Enterprise Co Ltd KO:241590	Korea	₩882.77 Billion
Jw Life Science Corp KO:234080	Korea	₩94.80 Billion

Liability Composition Analysis (2011–2025)

This chart breaks down OBI Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 4174 equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.70	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.33	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.18	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how OBI Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for OBI Pharma (2011–2025)

The table below shows the annual total liabilities of OBI Pharma from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$696.13 Million ≈ $21.93 Million	-16.47%
2024-12-31	NT$833.38 Million ≈ $26.26 Million	+28.12%
2023-12-31	NT$650.45 Million ≈ $20.49 Million	+30.73%
2022-12-31	NT$497.57 Million ≈ $15.68 Million	-19.22%
2021-12-31	NT$615.95 Million ≈ $19.41 Million	+22.68%
2020-12-31	NT$502.09 Million ≈ $15.82 Million	+9.35%
2019-12-31	NT$459.14 Million ≈ $14.47 Million	+94.53%
2018-12-31	NT$236.03 Million ≈ $7.44 Million	+82.04%
2017-12-31	NT$129.66 Million ≈ $4.08 Million	-22.51%
2016-12-31	NT$167.32 Million ≈ $5.27 Million	+31.74%
2015-12-31	NT$127.00 Million ≈ $4.00 Million	+187.09%
2014-12-31	NT$44.24 Million ≈ $1.39 Million	+6.71%
2013-12-31	NT$41.46 Million ≈ $1.31 Million	-6.63%
2012-12-31	NT$44.40 Million ≈ $1.40 Million	+211.09%
2011-12-31	NT$14.27 Million ≈ $449.68K	--

About OBI Pharma

TWO:4174 Taiwan Biotechnology

Market Cap

$115.04 Million

NT$3.65 Billion TWD

Market Cap Rank

#18749 Global

#1015 in Taiwan

Share Price

NT$27.75

Change (1 day)

+4.13%

52-Week Range

NT$23.25 - NT$50.50

All Time High

NT$743.00